{"id":46816,"date":"2022-08-02T09:01:42","date_gmt":"2022-08-02T07:01:42","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\/"},"modified":"2022-08-02T09:01:42","modified_gmt":"2022-08-02T07:01:42","slug":"wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\/","title":{"rendered":"Wilhelm von Haller is Chief Financial Officer of Lysando AG"},"content":{"rendered":"<div>\n<p>TRIESENBERG, Liechtenstein&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/Artilysin?src=hash\" target=\"_blank\" rel=\"noopener\">#Artilysin<\/a>&#8211;Lysando AG \u2013 market leader in the field of antimicrobial proteins \u2013 is pleased to announce that Wilhelm von Haller has joined the team as Chief Financial Officer this March. Baron von Haller is an expert in Corporate Finance, apprenticed during more than 30 years as leading executive in various roles at Deutsche Bank Group.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220802005152\/en\/1530778\/5\/Freiherr_Wilhelm_von_Haller.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220802005152\/en\/1530778\/21\/Freiherr_Wilhelm_von_Haller.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20220802005152\/en\/1530777\/5\/Lysando_Logo_Final_071718_np.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220802005152\/en\/1530777\/21\/Lysando_Logo_Final_071718_np.jpg\"><\/a><\/p>\n<p>\n&#8220;Wilhelm von Haller brings exactly the type of experience in global finance and business operations we need now. Moreover, as an advisor he has had the chance to get to know the Artilysin\u00ae technology for many years. Taken together, these are important factors to succeed in the new role and to fuel our future growth,&#8221; says Chairman of the Board of Directors of Lysando AG, Count Markus Matuschka de Greiffenclau. &#8220;Recent developments have confirmed that we have taken the right choice with Wilhelm von Haller, as he has already been setting many important new impulses for Lysando.&#8221;\n<\/p>\n<p>\nWilhelm von Haller assumed the position of CFO on March 1, 2022. Furthermore, Baron von Haller actively serves on several supervisory boards and advisory committees.\n<\/p>\n<p>\n&#8220;The past few years have highlighted the importance of innovation in medicine \u2013 particularly with regard to infectious diseases. Lysando has developed one of the most promising technologies in the field of combatting bacterial infections,&#8221; says CFO Wilhelm von Haller. &#8220;Being part of the Lysando team and having the opportunity to contribute the know-how I have been able to accumulate over the past decades into a progressive company fills me with pride.&#8221;\n<\/p>\n<p>\n<b>About Lysando AG<\/b>\n<\/p>\n<p>\nLysando AG is the market leader for antimicrobial proteins, so-called Artilysin\u00aes. They can effectively eliminate problem-causing bacteria without associated high risk of resistance formation and microbial disbalances. Artilysin\u00aes constitute an innovative, proprietary and environmentally friendly technology with a wide range of applications: in human and veterinary medicine, but for example also in cosmetics.\n<\/p>\n<p>\nLysando AG&#8217;s research facility is Lysando Innovations Lab GmbH located in Regensburg&#8217;s BioPark. BioPark Regensburg fosters companies in biotechnology, medical technology, diagnostics &amp; analytics as well as the local healthcare management.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nVerena Schossmann<br \/>\n<br \/>+41(0)79 211 83 42<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;a&#x69;l&#x74;o&#x3a;V&#x65;r&#x65;n&#x61;&#46;&#x53;&#99;&#x68;&#111;&#x73;&#115;&#x6d;&#97;&#x6e;&#110;&#x40;&#108;y&#x73;a&#x6e;d&#x6f;&#46;&#x63;o&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">Verena&#46;S&#99;&#104;&#111;&#115;&#115;&#109;&#97;&#110;&#110;&#64;&#x6c;&#x79;&#x73;&#x61;&#x6e;&#x64;&#x6f;&#x2e;&#x63;&#x6f;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>TRIESENBERG, Liechtenstein&#8211;(BUSINESS WIRE)&#8211;#Artilysin&#8211;Lysando AG \u2013 market leader in the field of antimicrobial proteins \u2013 is pleased to announce that Wilhelm von Haller has joined the team as Chief Financial Officer this March. Baron von Haller is an expert in Corporate Finance, apprenticed during more than 30 years as leading executive in various roles at Deutsche &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46816","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Wilhelm von Haller is Chief Financial Officer of Lysando AG - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Wilhelm von Haller is Chief Financial Officer of Lysando AG - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"TRIESENBERG, Liechtenstein&#8211;(BUSINESS WIRE)&#8211;#Artilysin&#8211;Lysando AG \u2013 market leader in the field of antimicrobial proteins \u2013 is pleased to announce that Wilhelm von Haller has joined the team as Chief Financial Officer this March. Baron von Haller is an expert in Corporate Finance, apprenticed during more than 30 years as leading executive in various roles at Deutsche ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-02T07:01:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220802005152\/en\/1530778\/21\/Freiherr_Wilhelm_von_Haller.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Wilhelm von Haller is Chief Financial Officer of Lysando AG\",\"datePublished\":\"2022-08-02T07:01:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\\\/\"},\"wordCount\":356,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220802005152\\\/en\\\/1530778\\\/21\\\/Freiherr_Wilhelm_von_Haller.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\\\/\",\"name\":\"Wilhelm von Haller is Chief Financial Officer of Lysando AG - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220802005152\\\/en\\\/1530778\\\/21\\\/Freiherr_Wilhelm_von_Haller.jpg\",\"datePublished\":\"2022-08-02T07:01:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220802005152\\\/en\\\/1530778\\\/21\\\/Freiherr_Wilhelm_von_Haller.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220802005152\\\/en\\\/1530778\\\/21\\\/Freiherr_Wilhelm_von_Haller.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Wilhelm von Haller is Chief Financial Officer of Lysando AG\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Wilhelm von Haller is Chief Financial Officer of Lysando AG - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\/","og_locale":"en_US","og_type":"article","og_title":"Wilhelm von Haller is Chief Financial Officer of Lysando AG - Pharma Trend","og_description":"TRIESENBERG, Liechtenstein&#8211;(BUSINESS WIRE)&#8211;#Artilysin&#8211;Lysando AG \u2013 market leader in the field of antimicrobial proteins \u2013 is pleased to announce that Wilhelm von Haller has joined the team as Chief Financial Officer this March. Baron von Haller is an expert in Corporate Finance, apprenticed during more than 30 years as leading executive in various roles at Deutsche ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-02T07:01:42+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220802005152\/en\/1530778\/21\/Freiherr_Wilhelm_von_Haller.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Wilhelm von Haller is Chief Financial Officer of Lysando AG","datePublished":"2022-08-02T07:01:42+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\/"},"wordCount":356,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220802005152\/en\/1530778\/21\/Freiherr_Wilhelm_von_Haller.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\/","url":"https:\/\/pharma-trend.com\/en\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\/","name":"Wilhelm von Haller is Chief Financial Officer of Lysando AG - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220802005152\/en\/1530778\/21\/Freiherr_Wilhelm_von_Haller.jpg","datePublished":"2022-08-02T07:01:42+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220802005152\/en\/1530778\/21\/Freiherr_Wilhelm_von_Haller.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220802005152\/en\/1530778\/21\/Freiherr_Wilhelm_von_Haller.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/wilhelm-von-haller-is-chief-financial-officer-of-lysando-ag\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Wilhelm von Haller is Chief Financial Officer of Lysando AG"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46816","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46816"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46816\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46816"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46816"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46816"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}